[HTML][HTML] Dupilumab (Dupixent) for Asthma

K Barry, D Gorelik - American Family Physician, 2020 - aafp.org
Dupilumab (Dupixent) is a monoclonal antibody injection labeled for the treatment of
moderate to severe asthma in patients 12 years and older with an eosinophilic phenotype or
who require oral corticosteroid treatment. It was previously labeled for the treatment of atopic
dermatitis and chronic rhinosinusitis with nasal polyposis.

[PDF][PDF] Dupilumab (Dupixent)

R Team - Canadian Journal of Health Technologies, 2021 - canjhealthtechnol.ca
Dupilumab (Duxipent) Page 1 August 2021 Volume 1 Issue 8 Clinical Review
Pharmacoeconomic Review CADTH Reimbursement Review Dupilumab (Duxipent) Sponsor:
Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc. Therapeutic area: Type 2 or
eosinophilic asthma Page 2 CADTH Reimbursement Review Dupilumab (Duxipent) 2 ISSN:
2563-6596 Disclaimer: The information in this document is intended to help Canadian health care
decision-makers, health care professionals, health systems leaders, and policy-makers make …